Crystalline Compound 49a Forms for Stability and Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions face challenges with instability and poor solubility of active ingredients, limiting their shelf life and effective drug delivery, necessitating the identification of stable polymorphic forms and consistent crystallization processes.
Innovation Solution
Development of crystalline forms of Compound 49a, characterized by X-Ray powder diffraction, differential scanning calorimetry, and other analytical techniques, to enhance stability and solubility, and formulation with pharmaceutically-acceptable carriers for improved bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If pharmaceutical compositions use conventional formulations, then manufacturing is simpler, but stability and solubility are poor
Solution Approach 1:
The patent applies parameter changes by developing specific crystalline forms of the active ingredient with defined crystal structures (Forms A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z). These crystalline forms exhibit different physical and chemical properties including enhanced stability, solubility, and dissolution rates compared to conventional formulations. The systematic variation of crystalline parameters resolves the contradiction between improved stability and manufacturing complexity.
Solution Approach 2:
The patent employs composite materials by formulating the active ingredient in combination with specific excipients and carriers to create pharmaceutical compositions with optimized properties. The use of crystalline forms combined with pharmaceutically acceptable carriers creates composite structures that simultaneously improve stability, solubility, and manufacturability, resolving the technical contradiction.
2Productivity
If pharmaceutical compositions use conventional formulations, then formulation process is easier, but dissolution rate and bioavailability are limited
Solution Approach 1:
The patent utilizes parameter changes by establishing specific crystalline forms with optimized lattice structures that enhance dissolution rates. The different polymorphic forms (Forms A through Z) exhibit varying dissolution characteristics, allowing selection of the optimal form for rapid drug release and improved bioavailability while maintaining manageable formulation processes.
Solution Approach 2:
The patent applies phase transitions by utilizing the different crystalline polymorphic forms of the active ingredient. Each crystalline form represents a different phase with distinct dissolution and bioavailability properties. By selecting and controlling the crystalline phase, the patent achieves enhanced dissolution rates and bioavailability while managing formulation complexity.
3Duration of action of stationary object
If pharmaceutical compositions use conventional formulations, then shelf life is limited, but formulation development is less complex
Solution Approach 1:
The patent applies parameter changes by systematically developing and characterizing multiple crystalline forms (Forms A through Z) with enhanced stability profiles. These crystalline forms exhibit improved resistance to degradation, moisture, and thermal stress, thereby extending shelf life. The structured approach to crystalline form development manages formulation complexity through methodical characterization and selection.
Solution Approach 2:
The patent employs preliminary action by pre-characterizing multiple crystalline forms and selecting the most stable form for pharmaceutical formulation. This proactive approach to stability optimization through preliminary crystalline form selection and characterization extends shelf life while managing formulation complexity through advance planning and systematic evaluation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of Compound 49a improve stability and dissolution rate, enabling effective drug delivery and treatment of conditions such as autoimmune disorders, inflammatory disorders, and cancer.
Implementation Method 1
heating a solution comprising the compound having the structure of Formula (M)-Ib to a temperature at which the compound equilibrates to form a mixture of atropisomers
Implementation Method 2
X-Ray powder diffraction (XRPD)
Implementation Method 3
differential scanning calorimetry (DSC)
Implementation Method 4
thermogravimetric analysis (TGA)
Data Source
AI summary
The present disclosure provides a crystalline form of the methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compound of the structure:XRPD, TGA, and DSC data on the crystalline form, as well as methods preparing the crystalline form, including a multi-kilo scale preparation. Also provided are pharmaceutical compositions and methods of treating p38 mediated diseases, such as lymphoma and auto-inflammatory disease, including rheumatoid arthritis. and methods of maximizing the yield thereof comprising administering of the compound. Also provided is a method of maximizing the yield of said compound via a recycling procedure.